Finally, some uncommon side effects are heart related illness forming half way through the study.
[2] The patients that were chosen are older than 21, life expectancy greater than three months, histologically confirmed metastatic, and normal hematologic and clotting parameters.
In addition people that have New York Heart Association Functional Classification II, III, and IV, uncontrolled seizers, active neurological diseases, and significant intercurrent illness are excluded.
The Phase 1 trials show that Demcizumab has a tolerable short term safety profile with common side effects of hypertension and fatigue.
[citation needed] The Yosemite trial is a double blind, randomized, 3 arm study in subjects with metastatic pancreatic cancer.
The primary purpose of the study is to assess the efficacy and safety of demcizumab with Abraxane plus gemcitabine compared to only standard care.
[4][5][6] In April 2017, OncoMed announced that the trial had failed to meet its primary endpoint and demcizumab had no significant effect on survival.
It is a randomized, 3 arm study in subjects with first-line metastatic Stage IV non-squamous non-small-cell lung cancer.